全球精準心臟病學市場：趨勢與成長機會

Global Precision Cardiology Market: Trends and Growth Opportunities

出版日期: 2026年02月17日 | 出版商:

Frost & Sullivan | 英文 57 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

跨行業合作以及尖端數位工具和技術的應用正在推動市場成長。

心血管疾病（CVD）仍然是全球發病和死亡的主要原因之一，自1990年以來，報告病例數加倍。目前，心血管疾病佔全球所有死亡人數的三分之一，佔全球所有死亡人數的32%，其中約85%是由心肌梗塞和缺血性中風引起的。這種成長趨勢與人口老化以及高血壓、肥胖和糖尿病等文明病因子的流行密切相關。其經濟影響巨大；預計到2050年，美國與心血管疾病相關的年度醫療保健費用將達到1.49兆美元，而歐盟的總費用在2024年已超過3,261億美元。

基因編輯技術、生物標記發現、數位生物標記和數位健康平台的進步正在加速向精準心臟病學的轉型，從而實現更個人化和預測性的患者管理。 Avidity Biosciences 和 Verve Therapeutics 等生物製藥創新公司正在開發下一代基於 RNA 和基因標靶治療，而包括 Apple、Fitbit 和 Garmin 等公司穿戴式裝置在內的消費者健康技術則支持對生理參數的持續監測。人工智慧 (AI) 和先進數據分析的整合將進一步增強心血管代謝疾病的早期檢測、個人化監測、風險預測和疾病管理。數位雙胞胎等數位技術正在改變診斷準確性和預後建模，使臨床醫生能夠模擬治療路徑並提供個人化介入。基於機制的建模和多尺度模擬的日益普及凸顯了它們在製定最佳治療策略和推進精準心臟病學方面的重要作用。

在臨床診療的連續過程中，醫療服務提供者致力於在降低治療成本的同時改善治療效果，因此，專注於最佳化藥物劑量、減輕藥物負擔和管理突發風險的解決方案正日益受到關注。隨著數位化和精準醫療干預措施的報銷框架逐步擴展，用於治療監測的預測分析正被臨床醫生、患者和保險公司更廣泛地接受。

為了加強實證醫學證據的累積並促進公平獲取，製藥公司正與學術機構、專業協會、政府機構和保險公司建立策略夥伴關係。這些合作旨在將專家小組納入行業決策流程，並建立標準化、全面的診療路徑。與美國心臟協會 (AHA) 和美國心臟病學會 (ACC) 等機構的合作，使安進和諾和諾德等公司能夠推進政策支持、調整報銷方案，並促進精準心臟病解決方案的更廣泛應用。

Cardiovascular diseases (CVDs) remain the leading cause of global morbidity and mortality, with reported cases having doubled since 1990. Today, CVDs account for 1 in 3 deaths worldwide, representing 32% of total global mortality, with heart attacks and ischemic strokes responsible for approximately 85% of these outcomes. The rising burden is strongly associated with population aging and an increasing prevalence of lifestyle-related risk factors, including hypertension, obesity, and diabetes. Economically, the impact is profound-annual CVD-related healthcare expenditures in the United States are projected to reach $1.49 trillion by 2050, while costs across the European Union have already exceeded $326.1 billion (2024).

Advancements in gene editing, biomarker discovery, digital biomarkers, and digital health platforms are accelerating the shift toward precision cardiology, enabling more personalized and predictive patient management. Biopharmaceutical innovators such as Avidity Biosciences and Verve Therapeutics are developing next-generation RNA-based and gene-targeted therapies, while consumer health technologies-including wearables from Apple, Fitbit, and Garmin-support continuous monitoring of physiological parameters. The integration of AI and advanced data analytics further enhances early detection, personalized monitoring, risk prediction, and disease management for cardiometabolic conditions. Digital technologies such as digital twins are transforming diagnostic accuracy and prognostic modeling, allowing clinicians to simulate treatment pathways and deliver tailored interventions. The increasing adoption of mechanistic modeling and multiscale simulations is helping define optimal therapeutic strategies, underscoring their role in propelling precision cardiology.

Within the clinical care continuum, solutions focused on dose optimization, reduced medication burden, and episodic risk management are gaining traction as healthcare providers seek to improve outcomes while minimizing treatment costs. Predictive analytics for treatment monitoring is gaining wider acceptance among clinicians, patients, and payers, supported by the gradual expansion of reimbursement frameworks for digital and precision-based interventions.

To strengthen evidence generation and promote equitable access, pharmaceutical companies are forming strategic partnerships with academic institutions, professional societies, government bodies, and payer organizations. These collaborations aim to integrate expert panels into industry decision-making processes and establish standardized, inclusive care pathways. Partnerships with agencies such as the American Heart Association (AHA) and the American College of Cardiology (ACC) have enabled companies, including Amgen and Novo Nordisk, to advance policy support, reimbursement alignment, and broader adoption of precision cardiology solutions.

Research Scope

Scope of Analysis
Segmentation

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8TM
The Impact of the Top 3 Strategic Imperatives on the Precision Cardiology Industry

Growth Opportunity Analysis

CVD Landscape
CVD Prevalence and Mortality
CVD Core Unmet Needs
Precision Health Application/Value Proposition across the Cardiology Care Continuum
Growth Drivers
Growth Restraints
Key Trends
Vendor Ecosystem

Growth Opportunity Analysis-Use Cases

Investment Trends
New Product Launches/Partnerships/Investor Funding

Growth Opportunity Analysis-Use Cases

CVD Diagnostics: Precision Diagnostics Testing and Monitoring Solutions
CVD Diagnostics: Key Challenges
Industry Use Case: Cardio Diagnostics
Industry Use Case: Ultromics

Growth Opportunity Analysis-Use Cases

Precision Cardiology: Treatment Ecosystem
CVDs: Treatment Approaches
Treatment (Therapeutics/Interventional/Non-Interventional Procedures)
CVDs: Personalized Therapies, Pipeline
Industry Use Case: Avidity Biosciences
Industry Use Case: Tenaya Therapeutics

Growth Opportunity Analysis-Use Cases

Monitoring/Surveillance: Devices and Patient Support Programs
CVDs: Monitoring/Surveillance: Devices and Patient Support Programs
Industry Use Case: Astellas Pharma, DIGITIVA
Industry Use Case: Cardiosense, CardioTag

Growth Opportunity Universe

Growth Opportunity 1: Improving CVD Care Pathways Across Emerging Countries through PPPs
Growth Opportunity 2: Biomarker-guided Precision Diagnostics for CVD
Growth Opportunity 3: Advanced Therapy Medicinal Products (ATMPs) for Rare Cardiovascular Diseases